Monogram's Herceptin theranostic promising
This article was originally published in Clinica
Executive Summary
Monogram Biosciences' Herceptin theranostic has shown promise in studies presented at the San Antonio Breast Cancer Symposium, held in Texas, from December 13-16. The trials found that the assay - called HERmark - was not only able to identify patients with the HER2 gene, but also distinguish patients into distinct sub-populations with different clinical outcomes.